DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

What is the ALIVUS LIFE SCIENCES LTD (ALIVUS) share price today?

ALIVUS LIFE SCIENCES LTD (ALIVUS) is trading at ₹1,133.3 on the NSE, down 2.65% on the day. Source: DocStoX.

What is the PE ratio of ALIVUS LIFE SCIENCES LTD?

ALIVUS LIFE SCIENCES LTD has a price-to-earnings (PE) ratio of 28.6 in the Healthcare sector.

What is the market capitalisation of ALIVUS LIFE SCIENCES LTD?

ALIVUS LIFE SCIENCES LTD has a market capitalisation of approximately ₹13,898 crore.

ALIVUS LIFE SCIENCES LTD

ALIVUS·NSE·Healthcare

₹1,133.30▼ -30.80 (-2.65%)

Healthcare · Pharmaceuticals

Debt-free and consistently profitable

Day₹1111.20

₹1170.40

52W₹819

₹119484%

Open

₹1164.90

High

₹1170.40

Low

₹1111.20

Prev Close

₹1164.10

Volume

77.9K

VWAP

₹1132.59

Snapshot

Key fundamentals

Market Cap

₹13,898 Cr

P/E Ratio

28.60Fair

P/B Ratio

4.21

EPS

₹39.63

Book Value

₹271.48

ROE

17.24%Strong

ROCE

25.00%Efficient

Dividend Yield

0.44%

Debt / Equity

0.02Low

Face Value

₹2.00

52W High

₹1193.90

52W Low

₹819.00

Sector

Healthcare

Industry

Pharmaceuticals

Avoid

Narrow moatMedium uncertainty

Fair value estimate

₹378

▼ 66.7%downside

Trading at ₹1,133 — 67% above our estimate

BearFair valueBull

₹321₹378₹492

/100

Business quality — Solid

Growth 0Profitability 81Efficiency 51Valuation 76

Plain English

Our view

Debt-free and consistently profitable
Virtually debt-free balance sheet

Strengths

Virtually debt-free balance sheet
Capital is working hard (ROCE 25%)
Promoters hold a controlling stake

How we got there

Fair value methods

Residual income

17% ROE fading to 12% over ~10 yrs, on ₹271 book

₹346

Relative P/E

Needs ≥3 peers with P/E

—

Graham floor

Conservative floor: √(22.5 × EPS × book value/share)

₹492

Analyst target

No analyst coverage

—

Blended fair value₹378

What the numbers say

Investment thesis

Bull case

Virtually debt-free balance sheet
Capital is working hard (ROCE 25%)
Promoters hold a controlling stake

Bear case

No notable red flags from the current metrics.

Free — see our deterministic Fair Value range, business quality score, and the full bull/bear case for this stock.

Snapshot

Key statistics

P/E

28.6Fair

Below 15× is value territory; above 35× prices in strong growth

ROE

17.2%Strong

Above 15% is considered healthy for Indian equities

ROCE

25.0%Efficient

Above 18% means capital is working hard

Debt/Eq

0.02Low

Below 0.5 is comfortable; above 1.5 strains the balance sheet

Mkt Cap

₹13,898 Cr

P/B

4.21

EPS

₹39.63

Div Yield

0.44%

What changed

Recent changes

Foreign investors+0.2% stake last quarter

What matters

News impact

Overview

Valuation

Reasonable

P/E 28.6×

Growth

Steady

+6% rev CAGR

Profitability

Healthy

17.2% ROE

Financial health

Rock solid

D/E 0.02

Momentum

N/A

No technicals

Today

Trading activity

Delivery %53.0%

Turnover₹882.44L Cr

Trades10,247

VWAP₹1132.59

Face value₹2.00

Market depth

Market depth available during market hours

Snapshot

Technical signals

Compounded annual growth

Growth (CAGR)

Revenue

+5.7%

+6.2%

10Y

—

Profit

+6.5%

+9.9%

10Y

—

EPS

—

10Y

—

Profile

Pros

Company is almost debt free.
Company has been maintaining a healthy dividend payout of 27.4%

Watch-outs

Cons

The company has delivered a poor sales growth of 6.24% over past five years.
Company has high debtors of 153 days.

Forecast

News

Peers

Financials

Growth

Shareholding

Ownership

Ownership breakdown

Quarter ending 30 Jun 2026

Foreign investors bought 0.24 pts last quarter. The QoQ column shows each group's change versus the prior quarter.

75%

Promoter

Promoters

74.9%0.00

Public

12.4%-0.13

FII / FPI

5.5%+0.24

DII

7.2%-0.09

Quarterly trend

Ownership over time

Q1 FY27

Promoter74.87%

FII5.54%

DII7.18%

Public12.42%

Corporate Actions

Bulk & Block Deals

Filings

MF Holdings

Technicals

FAQs

Quick reference

Frequently asked questions